The Food Safety and Standards Authority of India (FSSAI) issued a regulatory directive for the removal and prohibition of the ORSL electrolyte beverages after misbranding issues. The action applies to electrolyte drinks marketed using the term “ORS” despite not meeting the World Health Organization (WHO) recommended medical ORS composition standards.

ORSL Electrolyte Beverage Regulatory Action: Misbranding, Public Health Risk, and Market Withdrawal in India

Recall Jan 31, 2026

Category of the product: Electrolyte Beverage (ORS-labelled Drink)

Type of the product: Food & Beverages – Misbranding / Labeling & Claim Compliance

Reason for announcement

Misbranding of beverages – Use of the term “ORS” (Oral Rehydration Salts) on products not conforming to WHO-recommended ORS formulation

NEW DELHI, INDIA (October 14, 2025) —

The Food Safety and Standards Authority of India (FSSAI) issued a regulatory directive for the removal and prohibition of the ORSL electrolyte beverages after misbranding issues. The action applies to electrolyte drinks marketed using the term “ORS” despite not meeting the World Health Organization (WHO) recommended medical ORS composition standards.

The regulatory action has been taken after FSSAI found out that the labeling and branding of ORSL beverages may mislead a consumer into believing that the product was medically approved oral rehydration solution. Although no contamination or immediate illness reports were recorded, FSSAI has pointed out that misleading labeling is a high-risk factor for public health, especially in the case of children or vulnerable populations that may rely on ORS during dehydration episodes.

Reason for warning

Under the Food Safety and Standards Act of 2006, the use of the term “ORS” on non-medical electrolyte beverages amounts to misleading or deceptive practices. Such labeling may cause consumers to substitute these products for medically validated ORS, potentially delaying appropriate treatment and worsening dehydration outcomes—especially among children and individuals affected by diarrhoea, heat stress, or illness. [1]

Root cause analysis

The regulatory action behind this was due to long-standing public health concerns judicial scrutiny regarding the misuse of therapeutic terminology in food and beverage labeling. The root cause of all this was in the branding and claim approach wherein ORSL electrolyte beverages used “ORS” in product names and marketing materials despite not conforming to WHO-recommended ORS electrolyte and glucose ratios.

While manufacturers cited historical market presence, regulators concluded that continued use of the term created consumer confusion and violated labeling and advertising regulations. The product formulation itself was not identified as chemically unsafe; instead, enforcement focused on misrepresentation of therapeutic equivalence, with emphasis on consumer perception rather than contamination or adulteration. [2]  

Product description

Brand

Product

Size

Issue

Affected Regions

ORSL

Electrolyte Beverage (ORS-labelled)

Multiple SKUs

Misbranding – unauthorized use of “ORS”

Pan-India

Health issue identified

The primary health issue seen from this regulation involves the misinterpretation by consumers rather than the toxins themselves. Medical experts and regulators highlighted that substitution of sugar or non-compliant electrolyte drinks for actual Medical ORS can worsen dehydration conditions, especially in paediatric cases. Improper electrolyte balance and higher sugar content may impair fluid absorption, delay appropriate medical care, and increase health risks during dehydration events.

The risk is especially pronounced in rural and low-resource settings, where ORS is widely relied upon as a life-saving intervention. Misbranded products can undermine public health messaging and compromise treatment outcomes without consumers being aware of the distinction.

Health issue identified

The primary health issue seen from this regulation involves the misinterpretation by consumers rather than the toxins themselves. Medical experts and regulators highlighted that substitution of sugar or non-compliant electrolyte drinks for actual Medical ORS can worsen dehydration conditions, especially in paediatric cases. Improper electrolyte balance and higher sugar content may impair fluid absorption, delay appropriate medical care, and increase health risks during dehydration events.

The risk is especially pronounced in rural and low-resource settings, where ORS is widely relied upon as a life-saving intervention. Misbranded products can undermine public health messaging and compromise treatment outcomes without consumers being aware of the distinction.

FRLBLOGIMAGE5

FSSAI enforcement directions

As part of the regulatory action, the FSSAI directed state and union territory food safety authorities to implement immediate enforcement measures, including:

  • Removal of misbranded ORS-labelled beverages from retail shelves including pharmacies and quick-commerce retail outlets.
  • Seizure and prohibition of further sale or distribution of products labelled with “ORS” unless they comply with the regulated medical ORS formulation.
  • Initiation of action under the Food Safety and Standards Act, 2006, including penalties like imposition of fine, suspension of licensing, and prosecution against violators.

Such directions were also reinforced through official enforcement notices to local authorities to inspect retail outlets and ensure that non-compliant products were no longer available in the retail stores. [4]

Delhi High Court Upholds FSSAI Action

The FSSAI ban led to legal challenges from affected companies, including JNTL Consumer Health India Pvt Ltd, the maker of ORSL, who want permission to sell their existing stocks labeled with “ORS.”

On November 12, 2025, the Delhi High Court, led by Chief Justice Devendra Kumar Upadhyaya and Justice Tushar Rao Gedela, refused to allow the sale or disposal of ORSL products carrying the “ORS” label. The Court held that the prohibition is justified on public health grounds, noting that misbranding could mislead consumers—especially in rural areas—into using non-compliant beverages as therapeutic rehydration solutions.

Further, the Court also held that the continued sale, even without toxicity, could result in a delay of medical treatment for children and vulnerable groups. In a related ruling, the High Court also dismissed Dr. Reddy’s Laboratories Ltd’s challenge against the ORS labeling ban for Rebalanz VITORS, reaffirming the legality of the FSSAI’s action. [5]

Ongoing enforcement and market challenges

Despite this regulatory directive and judicial backing, enforcement challenges remain. Reports indicated that some non-compliant beverages with the ORS labeling continued to appear in pharmacies and quick-commerce platforms in some states. These instances highlight gaps in ground-level enforcement and the need for coordinated action by state authorities to ensure complete market withdrawal. Regulators and public health experts caution that inconsistent enforcement may undermine consumer confidence and public health objectives. 

Consumer guidance

  • Do not treat the ORSL electrolyte beverages as a medical ORS.
  • Consumers experiencing rehydration needs for diarrhoea, heat exhaustion, and illnesses should rely on WHO-recommended ORS formulations and/or advice from healthcare professionals.
  • Retailers and distributors must ensure complete removal of ORS-labelled non-compliant beverages from sale.
  • Manufacturers must ensure full labeling compliance before reintroducing any product to the market. [6]

FRL commentary

The ORSL regulatory action demonstrates that misbranding alone can trigger recall-equivalent enforcement, even in the absence of contamination. Therapeutic terminology such as “ORS” carries public health implications and must be supported by formulation compliance, not marketing intent. Early regulatory review, claim validation, and third-party verification are essential to avoid enforcement action and market withdrawal.

Conclusion

The ORSL electrolyte beverage action marks a significant case of misbranding-driven enforcement in India. Though not being a contamination recall, the FSSAI directive-which had been upheld by the Delhi High Court-led to market withdrawal highlighting that misleading labeling alone can pose serious public health risks. The case reinforces the need for accurate claims, scientific substantiation, and strong labeling governance to ensure regulatory compliance.

For updates on food recalls, misbranding actions, and regulatory compliance guidance, visit Food Research Lab.

References

  1. Vajiram & Ravi. (2025, October). FSSAI bans misleading ORS labels on sugary beverages. https://vajiramandravi.com/current-affairs/fssai-bans-misleading-ors-labels-on-sugary-beverages/
  2. India Today. (2025, October 16). FSSAI bans use of ORS in food and beverage products to prevent misleading health claims. https://www.indiatoday.in/health/story/fssai-bans-use-of-ors-in-food-and-beverage-products-to-prevent-misleading-health-claims-2804083-2025-10-16
  3. Agron Food Processing. (2025). Delhi HC rejects plea to sell existing ORSL stocks citing misbranding and public health risks. https://agronfoodprocessing.com/delhi-hc-rejects-plea-to-sell-existing-orsl-stocks-citing-misbranding-and-public-health-risks/
  4. The Economic Times (Legal). (2025). Delhi High Court bans misbranding of ORSL beverages, a public health concern. https://legal.economictimes.indiatimes.com/news/litigation/delhi-high-court-bans-misbranding-of-orsl-beverages-a-public-health-concern/125281464
  5. BW Legal World. (2025). Delhi High Court refuses relief to Johnson & Johnson on sale of ORSL electrolyte drink stock. https://www.bwlegalworld.com/article/delhi-high-court-refuses-relief-to-johnson-johnson-on-sale-of-orsl-electrolyte-drink-stock-579534
  6. Supreme Court Cases Online. (2025, October 17). FSSAI bans use of ORS in food product labelling. https://www.scconline.com/blog/post/2025/10/17/fssai-bans-use-of-ors-in-food-product-labelling/